

RECCE PHARMACEUTICALS LTD

ABN 73 124 849 065

Appendix 4E

Preliminary Final Report for the financial year ended 30 June 2021

Current Reporting Period: **30 June 2021**

Previous Reporting Period: **30 June 2020**

Results for Announcement to the Market

	12 months to 30 June 2021	12 months to 30 June 2020	% change
	\$	\$	
Revenue from ordinary activities	-	-	0%
Loss from ordinary activities after tax attributable to members	(13,513,366)	(4,316,737)	213%
Net loss for the period attributable to members	(13,513,366)	(4,316,737)	213%

Brief Explanation of Results

Operational Report

During the reporting period, significant advances were made in support of the development of the Company's broad-spectrum synthetic antibiotic program. Some of the highlights for the year were as follows:

- Entered into an Antiviral SARS-CoV-2 Screening Program Agreement, with a scientific Australian Government agency and a world Class institute focused on infection and immunity following selection of RECCE® 327 in the Priority 1 candidate group
- Entered into an agreement with Path BioAnalytics Inc, a precision medicine company based in Durham, North Carolina, USA, for the study of RECCE® 327 and RECCE® 529 against SARS-CoV-2
- Announced positive efficacy activity against Helicobacter pylori (H. pylori) bacteria in rats treated with new anti-infective RECCE® 435, including a favourable toxicity profile in a related study. RECCE® 435 is a synthetic polymer anti-infective formulated for oral use
- Successful placement of \$27.9m (before costs) in fully paid ordinary shares at \$1.30 per share
- Entered into an agreement with the Murdoch Children's Research Institute to conduct pre-clinical studies assessing the potential of RECCE® 435 for the treatment of Helicobacter pylori infections



ASX: RCE, **FSE:** R9Q

Head Office: Level 25, 88 Phillip Street, Aurora Place, SYDNEY NSW 2000 **T** +61 (02) 9256 2571

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

- Announced it had received Human Research Ethics Committee approval to start a Phase I/II topical clinical trial of its synthetic anti-infective RECCE® 327 for patients with infected burn wounds
- Expansion of wholly owned patent estate - Patent Family 3 Grants in Japan
- announced it had formalised an agreement with Fiona Stanley Hospital for a Phase I/II clinical trial to assess the potential of RECCE® 327's new spray-on, broad-spectrum antibiotic for the treatment of topical burn wound infections
- Dual Listed on the Frankfurt Stock Exchange (FSE), with trading commencing Monday 8 March at 8:00am (CET) under the code R9Q
- the European Patent Office granted Patent Family 3 "Anti-Virus Agent for Treatment Of Viral Infections", furthering marketing and manufacturing monopolies to February 2037

Financial Report

The operating loss has increased to \$13,513,366 (2020: loss of \$4,316,737) as a result of the increased focus on its R&D activities and share-based payments. The annual loss was after a R&D tax incentive of \$1,566,031 (2020: \$1,071,727).

The loss per share has increased during the year to 8.70 cents (2020: 3.39 cents).

The Group's focus is on progressing RECCE® 327 into human clinical trials.

Dividends

	Amount per Security	Percentage Franked
Final Dividend	Nil	N/A
Interim Dividend	Nil	N/A
Date the Dividend is Payable:	N/A	N/A
Record Date for determining entitlements to the Dividends:	N/A	N/A

The Company did not declare a dividend during the financial year and has not declared a dividend since the end of the financial year.

Net Tangible Assets per Security

As at 30 June 2021 (cents)	11.80
As at 30 June 2020 (cents)	1.70

